Glutamate carboxypeptidase II inhibition as a novel therapeutic target.
Rojas
C
C
Guilford Pharmaceuticals Inc., 6611 Tributary Street, Baltimore, Maryland 21224 USA.
Thomas
A G
AG
Majer
P
P
Tsukamoto
T
T
Lu
X M
XM
Vornov
J J
JJ
Wozniak
K M
KM
Slusher
B S
BS
D000818:Animals; D001921:Brain / Q000201:enzymology; D001930:Brain Injuries / Q000517:prevention & control; D002268:Carboxypeptidases / Q000378:metabolism*; D004195:Disease Models, Animal; D043425:Glutamate Carboxypeptidase II; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D007668:Kidney / Q000201:enzymology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*
C402107:2-(phosphonomethyl)pentanedioic acid; D018696:Neuroprotective Agents; D009943:Organophosphorus Compounds; D011480:Protease Inhibitors; D002268:Carboxypeptidases; D043425:Glutamate Carboxypeptidase II